4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
ProKidney Corp. (PROK) operates in the Biotechnology industry and is headquartered in Winston-Salem, United States with about 231 employees. Its market capitalization is roughly $489 million. In the fiscal year ended 2025-12-31, PROK reported $1M in revenue and ($69M) in net income.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States.
Interactive charts & full statements → Open the PROK valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $1M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($165M) | ($184M) | ($152M) | ($153M) |
| Net Income | ($69M) | ($61M) | ($36M) | ($108M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($45M) | ($45M) | ($38M) | ($40M) | ($41M) |
| Net Income | ($20M) | ($19M) | ($16M) | ($17M) | ($17M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $336M | $441M | $421M | $518M | — |
| Total Liabilities | $35M | $39M | $29M | $13M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PROK viewer.
About TickerBase · Data methodology & sources